RARE DISEASE
Germ cell tumor of testis
Germ cell tumor of testis
Germ cell tumor of testis
Synonyms: Testicular germ cell tumor
Synonyms: Testicular germ cell tumor
Synonyms: Testicular germ cell tumor
Drug discovery
1
drug
With orphan designation
Overview
Germ cell tumors (GCTs) account for over 95% of testicular cancers, primarily affecting males aged 15–44 years. These tumors arise from germ cell neoplasia in situ (GCNIS) and are classified into seminomas (radiation/chemotherapy-sensitive) and nonseminomas (aggressive, mixed histology). Diagnosis relies on imaging, serum markers (AFP, β-hCG), and histopathology. Platinum-based chemotherapy, radiotherapy, and surgery achieve cure rates exceeding 90% even in advanced stages [1][4][16].
Burden
Incidence increasing by 1%–3% annually globally, with Hispanics projected to surpass non-Hispanic whites in the US by 2026 [2][14].
99% 5-year survival for localized disease; 48%–92% for metastatic cases based on risk stratification [4][16].
Long-term morbidity from treatment includes cardiovascular toxicity, secondary malignancies, and infertility [16][19].
Therapies
Localized disease: Radical orchiectomy ± adjuvant chemotherapy (carboplatin for seminoma) or surveillance [4][8][13].
Metastatic disease: BEP regimen (bleomycin, etoposide, cisplatin) for nonseminomas; radiation or carboplatin for seminomas [6][18][13].
Relapsed/refractory: Salvage high-dose chemotherapy with autologous stem cell transplant or targeted therapies (e.g., paclitaxel-gemcitabine combinations) [3][6][13].
Categories: rare neoplastic diseases, rare transplant-related disorders, rare urogenital diseases
Research Papers
1,991 drug discovery papers about Germ cell tumor of testis, with 1 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,991 drug discovery papers about Germ cell tumor of testis, with 1 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-09 | Therapeutic targeting of folate receptor alpha (FRα) by antibody-polymer-drug conjugate in testicular germ cell tumors.
Antibody-drug conjugates (ADCs) are an effective treatment for recurrent/refractory testicular germ cell tumors (rrTGCTs). In this exploratory study, we report disease stabilization achieved with the ADC Mirvetuximab soravtansine (MIRV) in a heavily pretreated patient with rrTGCT and compare this ADC with a novel antibody-polymer-drug conjugate (APDC) targeting folate receptor α (FRα), MIRV-P-MMAE. APDC MIRV-P-MMAE with a drug-to-antibody ratio ∼23, was synthesized using orthogonal attachment of a highly hydrophilic copolymer to the hinge region of anti-FRα antibody. Its efficacy was compared with MIRV in vitro in TGCT cells and in vivo in a metastatic model of human testicular choriocarcinoma (CHC). Furthermore, we evaluated FRα expression in TGCT and assessed efficacy of MIRV in an rrTGCT patient. Our investigations revealed the highest antiproliferative effect of MIRV-P-MMAE in FRα-positive CHC cells, JAR and JEG3, with IC50 values of 19.8 pM and 22.5 pM, respectively. These IC50 values are 210- and 70-fold lower than those of MIRV. Cytotoxicity was also confirmed in SuSa, PA1, and NCR-G1 cell lines. High efficacy was demonstrated in animals intravenously injected with JAR-luc cells, in which APDC treatment significantly prolonged survival (p = 0.0002) and completely cured 3 of 8 animals. Our data showed FRα membrane staining in 5,1% of TGCT samples, but confirmed cytoplasmic positivity in all 5 viable rrTGCT post-chemotherapy patient samples, suggesting that APDC with high DAR could be explored in rrTGCT patients with low expression of the target antigen. Our data warrant further exploration of FRα-targeting APDC as a novel approach for treating FRα-expressing rrTGCT.
2026-07-23 | Data from Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors
<div>Abstract<p>To characterize clinically actionable cell surface proteins in testicular germ cell tumors (GCT), we retrospectively analyzed archival formalin-fixed, paraffin-embedded orchiectomy specimens from 30 patients, including 11 with pure seminoma and 19 with mixed GCTs. Immunohistochemistry was performed for 21 surface antigens using an automated platform. Staining intensity (0 to 3+) and the percentage of positive tumor cells were used to derive H-scores (0–300). Expression was summarized by patient classification and histologic component; high expression was defined as H-score ≥100. Claudin-6 (CLDN6) was diffusely and strongly expressed, with H-score ≥100 in 100% of pure seminomas and 89.5% of mixed GCTs. At the component level, 100% of seminoma and 92.9% of embryonal carcinoma samples reached this threshold. Epidermal growth factor receptor (EGFR) showed high expression in 68.4% of mixed GCTs and 45.5% of pure seminomas, with most enrichment in teratoma components (73.3%, ≥100; mean H-score, 212). TROP2 was markedly upregulated in mixed GCTs (78.9%, ≥100; mean, 194.7), particularly in teratoma components (86.7%, ≥100). Nectin-4 and glycoprotein nonmetastatic melanoma B (GPNMB) were expressed in smaller but notable subsets, including teratoma and seminoma, whereas most remaining antigens, including CD19, DLL3, FOLR1, and BCMA, showed minimal or no expression. These findings demonstrate a distinct surface antigen landscape in testicular GCTs, with CLDN6, EGFR, and TROP2 emerging as leading candidates for further translational evaluation. The enrichment of these targets highlights antigenic heterogeneity within GCTs and supports further validation in appropriate disease settings, including metastatic, posttreatment, and relapsed or refractory disease.</p>Significance:<p>Relapsed or refractory testicular GCT remains a clinical challenge with limited treatment options. We evaluated cell surface antigens of primary GCTs and identified CLDN6, EGFR, and TROP2 as candidate targets for antigen-directed approaches. These findings provide a rationale for future validation in metastatic and posttreatment disease settings.</p></div>
2026-07-10 | Metastatic Testicular Germ Cell Tumor in a Patient With Neurofibromatosis Type 1: Treatment With Trametinib Based on NF1 Gene Mutation.
Neurofibromatosis type 1 (NF1) is a genetic disorder that increases the risk of various tumors. However, its association with testicular germ cell tumors (GCTs) is rare. We report a case of metastatic GCT in an NF1 patient treated with precision medicine. A 40-year-old male with NF1 presented with a left testicular non-seminomatous GCT and lung metastases. The tumor showed progressive disease after chemotherapy (VIP, TGP) and surgical removal of metastases. Comprehensive genomic profiling (CGP) test found a pathogenic NF1 frameshift mutation (p.Q514fs*43). Based on this finding, the patient received the MEK inhibitor trametinib under patient-proposed healthcare services (BELIEVE Trial). Treatment resulted in normalization of serum alpha-fetoprotein (AFP) for 6 months before the tumor eventually progressed. The patient died at 39 months after diagnosis. This is the first report of trametinib for a metastatic GCT with an NF1 mutation, suggesting a possible but limited treatment effect. The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE), NCCH1901/jRCTs031190104.
2026-06-29 | Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors
To characterize clinically actionable cell surface proteins in testicular germ cell tumors (GCTs), we retrospectively analyzed archival formalin-fixed paraffin-embedded orchiectomy specimens from 30 patients, including 11 with pure seminoma and 19 with mixed GCTs. Immunohistochemistry was performed for 21 surface antigens using an automated platform. Staining intensity (0-3+) and percentage of positive tumor cells were used to derive H-scores (0-300). Expression was summarized by patient classification and histologic component; high expression was defined as H-score ≥100. CLDN6 was diffusely and strongly expressed, with H-score ≥100 in 100% of pure seminomas and 89.5% of mixed GCTs. At the component level, 100% of seminoma and 92.9% of embryonal carcinoma samples reached this threshold. EGFR showed high expression in 68.4% of mixed GCTs and 45.5% of pure seminomas, with most enrichment in teratoma components (73.3% ≥100; mean H-score 212.0). TROP2 was markedly upregulated in mixed GCTs (78.9% ≥100; mean 194.7), particularly in teratoma components (86.7% ≥100). Nectin-4 and GPNMB were expressed in smaller but notable subsets, including teratoma and seminoma, whereas most remaining antigens, including CD19, DLL3, FOLR1, and BCMA, showed minimal or no expression. These findings demonstrate a distinct surface antigen landscape in testicular GCTs, with CLDN6, EGFR, and TROP2 emerging as leading candidates for further translational evaluation. Enrichment of these targets highlights antigenic heterogeneity within GCTs and supports further validation in appropriate disease settings including metastatic, post-treatment, and relapsed or refractory disease.
2026-06-29 | MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment.
Testicular germ cell tumors (TGCTs) are the most common solid malignancies in young men and, despite high cure rates with cisplatin-based multimodal therapy, a clinically relevant subset of patients develops relapsed, platinum-refractory, or treatment-resistant disease with limited salvage options and substantial long-term morbidity. This unmet need has renewed interest in immunotherapy, yet the experience in TGCT has been notably less successful than in other malignancies. Although TGCTs often display PD-L1 expression, tumor-infiltrating lymphocytes, and other features suggestive of immune engagement, immune checkpoint inhibitors have produced largely disappointing results in unselected patients, underscoring the complexity of immune regulation in this immune-privileged disease. Recent conceptual advances place microRNAs (miRNAs) at the center of this problem. Beyond their established diagnostic and prognostic value, miRNAs are increasingly recognized as upstream regulators of immune checkpoints, antigen-presentation pathways, cytokine signaling, macrophage polarization, dendritic-cell and T-cell function, and extracellular-vesicle-mediated tumor-immune crosstalk. This positions miRNAs not only as biomarkers of disease activity, but also as plausible determinants of immunotherapy sensitivity or resistance. At the same time, the field remains marked by important controversies: PD-L1 expression alone is an unreliable predictor of response; the relative contribution of low tumor mutational burden, testicular immune privilege, and microenvironmental suppression remains unresolved; and many proposed TGCT-associated miRNAs with an immunoregulatory role are still inferential rather than causally validated in disease-specific models. Accordingly, major gaps persist in defining which miRNAs are true functional drivers of immune escape in seminomatous versus non-seminomatous TGCT, how they interact with therapy-induced tumor evolution, and which delivery platforms can achieve safe, tumor-directed modulation. We argue that the next phase of the field should move beyond descriptive biomarker studies toward mechanism-based, TGCT-specific translational strategies integrating miRNA mimics, antagomirs, extracellular vesicles, or miRNA-augmented cellular therapies with immune-priming approaches such as epigenetic therapy, radiotherapy, vaccines, or CAR-T platforms. Such a framework could enable more precise biological stratification and improve the efficacy, durability, and tolerability of immunotherapy in refractory TGCT.
2026-08-09 | Therapeutic targeting of folate receptor alpha (FRα) by antibody-polymer-drug conjugate in testicular germ cell tumors.
Antibody-drug conjugates (ADCs) are an effective treatment for recurrent/refractory testicular germ cell tumors (rrTGCTs). In this exploratory study, we report disease stabilization achieved with the ADC Mirvetuximab soravtansine (MIRV) in a heavily pretreated patient with rrTGCT and compare this ADC with a novel antibody-polymer-drug conjugate (APDC) targeting folate receptor α (FRα), MIRV-P-MMAE. APDC MIRV-P-MMAE with a drug-to-antibody ratio ∼23, was synthesized using orthogonal attachment of a highly hydrophilic copolymer to the hinge region of anti-FRα antibody. Its efficacy was compared with MIRV in vitro in TGCT cells and in vivo in a metastatic model of human testicular choriocarcinoma (CHC). Furthermore, we evaluated FRα expression in TGCT and assessed efficacy of MIRV in an rrTGCT patient. Our investigations revealed the highest antiproliferative effect of MIRV-P-MMAE in FRα-positive CHC cells, JAR and JEG3, with IC50 values of 19.8 pM and 22.5 pM, respectively. These IC50 values are 210- and 70-fold lower than those of MIRV. Cytotoxicity was also confirmed in SuSa, PA1, and NCR-G1 cell lines. High efficacy was demonstrated in animals intravenously injected with JAR-luc cells, in which APDC treatment significantly prolonged survival (p = 0.0002) and completely cured 3 of 8 animals. Our data showed FRα membrane staining in 5,1% of TGCT samples, but confirmed cytoplasmic positivity in all 5 viable rrTGCT post-chemotherapy patient samples, suggesting that APDC with high DAR could be explored in rrTGCT patients with low expression of the target antigen. Our data warrant further exploration of FRα-targeting APDC as a novel approach for treating FRα-expressing rrTGCT.
2026-07-23 | Data from Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors
<div>Abstract<p>To characterize clinically actionable cell surface proteins in testicular germ cell tumors (GCT), we retrospectively analyzed archival formalin-fixed, paraffin-embedded orchiectomy specimens from 30 patients, including 11 with pure seminoma and 19 with mixed GCTs. Immunohistochemistry was performed for 21 surface antigens using an automated platform. Staining intensity (0 to 3+) and the percentage of positive tumor cells were used to derive H-scores (0–300). Expression was summarized by patient classification and histologic component; high expression was defined as H-score ≥100. Claudin-6 (CLDN6) was diffusely and strongly expressed, with H-score ≥100 in 100% of pure seminomas and 89.5% of mixed GCTs. At the component level, 100% of seminoma and 92.9% of embryonal carcinoma samples reached this threshold. Epidermal growth factor receptor (EGFR) showed high expression in 68.4% of mixed GCTs and 45.5% of pure seminomas, with most enrichment in teratoma components (73.3%, ≥100; mean H-score, 212). TROP2 was markedly upregulated in mixed GCTs (78.9%, ≥100; mean, 194.7), particularly in teratoma components (86.7%, ≥100). Nectin-4 and glycoprotein nonmetastatic melanoma B (GPNMB) were expressed in smaller but notable subsets, including teratoma and seminoma, whereas most remaining antigens, including CD19, DLL3, FOLR1, and BCMA, showed minimal or no expression. These findings demonstrate a distinct surface antigen landscape in testicular GCTs, with CLDN6, EGFR, and TROP2 emerging as leading candidates for further translational evaluation. The enrichment of these targets highlights antigenic heterogeneity within GCTs and supports further validation in appropriate disease settings, including metastatic, posttreatment, and relapsed or refractory disease.</p>Significance:<p>Relapsed or refractory testicular GCT remains a clinical challenge with limited treatment options. We evaluated cell surface antigens of primary GCTs and identified CLDN6, EGFR, and TROP2 as candidate targets for antigen-directed approaches. These findings provide a rationale for future validation in metastatic and posttreatment disease settings.</p></div>
2026-07-10 | Metastatic Testicular Germ Cell Tumor in a Patient With Neurofibromatosis Type 1: Treatment With Trametinib Based on NF1 Gene Mutation.
Neurofibromatosis type 1 (NF1) is a genetic disorder that increases the risk of various tumors. However, its association with testicular germ cell tumors (GCTs) is rare. We report a case of metastatic GCT in an NF1 patient treated with precision medicine. A 40-year-old male with NF1 presented with a left testicular non-seminomatous GCT and lung metastases. The tumor showed progressive disease after chemotherapy (VIP, TGP) and surgical removal of metastases. Comprehensive genomic profiling (CGP) test found a pathogenic NF1 frameshift mutation (p.Q514fs*43). Based on this finding, the patient received the MEK inhibitor trametinib under patient-proposed healthcare services (BELIEVE Trial). Treatment resulted in normalization of serum alpha-fetoprotein (AFP) for 6 months before the tumor eventually progressed. The patient died at 39 months after diagnosis. This is the first report of trametinib for a metastatic GCT with an NF1 mutation, suggesting a possible but limited treatment effect. The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE), NCCH1901/jRCTs031190104.
2026-06-29 | Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors
To characterize clinically actionable cell surface proteins in testicular germ cell tumors (GCTs), we retrospectively analyzed archival formalin-fixed paraffin-embedded orchiectomy specimens from 30 patients, including 11 with pure seminoma and 19 with mixed GCTs. Immunohistochemistry was performed for 21 surface antigens using an automated platform. Staining intensity (0-3+) and percentage of positive tumor cells were used to derive H-scores (0-300). Expression was summarized by patient classification and histologic component; high expression was defined as H-score ≥100. CLDN6 was diffusely and strongly expressed, with H-score ≥100 in 100% of pure seminomas and 89.5% of mixed GCTs. At the component level, 100% of seminoma and 92.9% of embryonal carcinoma samples reached this threshold. EGFR showed high expression in 68.4% of mixed GCTs and 45.5% of pure seminomas, with most enrichment in teratoma components (73.3% ≥100; mean H-score 212.0). TROP2 was markedly upregulated in mixed GCTs (78.9% ≥100; mean 194.7), particularly in teratoma components (86.7% ≥100). Nectin-4 and GPNMB were expressed in smaller but notable subsets, including teratoma and seminoma, whereas most remaining antigens, including CD19, DLL3, FOLR1, and BCMA, showed minimal or no expression. These findings demonstrate a distinct surface antigen landscape in testicular GCTs, with CLDN6, EGFR, and TROP2 emerging as leading candidates for further translational evaluation. Enrichment of these targets highlights antigenic heterogeneity within GCTs and supports further validation in appropriate disease settings including metastatic, post-treatment, and relapsed or refractory disease.
2026-06-29 | MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment.
Testicular germ cell tumors (TGCTs) are the most common solid malignancies in young men and, despite high cure rates with cisplatin-based multimodal therapy, a clinically relevant subset of patients develops relapsed, platinum-refractory, or treatment-resistant disease with limited salvage options and substantial long-term morbidity. This unmet need has renewed interest in immunotherapy, yet the experience in TGCT has been notably less successful than in other malignancies. Although TGCTs often display PD-L1 expression, tumor-infiltrating lymphocytes, and other features suggestive of immune engagement, immune checkpoint inhibitors have produced largely disappointing results in unselected patients, underscoring the complexity of immune regulation in this immune-privileged disease. Recent conceptual advances place microRNAs (miRNAs) at the center of this problem. Beyond their established diagnostic and prognostic value, miRNAs are increasingly recognized as upstream regulators of immune checkpoints, antigen-presentation pathways, cytokine signaling, macrophage polarization, dendritic-cell and T-cell function, and extracellular-vesicle-mediated tumor-immune crosstalk. This positions miRNAs not only as biomarkers of disease activity, but also as plausible determinants of immunotherapy sensitivity or resistance. At the same time, the field remains marked by important controversies: PD-L1 expression alone is an unreliable predictor of response; the relative contribution of low tumor mutational burden, testicular immune privilege, and microenvironmental suppression remains unresolved; and many proposed TGCT-associated miRNAs with an immunoregulatory role are still inferential rather than causally validated in disease-specific models. Accordingly, major gaps persist in defining which miRNAs are true functional drivers of immune escape in seminomatous versus non-seminomatous TGCT, how they interact with therapy-induced tumor evolution, and which delivery platforms can achieve safe, tumor-directed modulation. We argue that the next phase of the field should move beyond descriptive biomarker studies toward mechanism-based, TGCT-specific translational strategies integrating miRNA mimics, antagomirs, extracellular vesicles, or miRNA-augmented cellular therapies with immune-priming approaches such as epigenetic therapy, radiotherapy, vaccines, or CAR-T platforms. Such a framework could enable more precise biological stratification and improve the efficacy, durability, and tolerability of immunotherapy in refractory TGCT.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Germ cell tumor of testis, including 1 approved therapy.
1 orphan drug designation for Germ cell tumor of testis, including 1 approved therapy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Ifosfamide [Ifex] | small molecules | FDA | 1987-01-20 | 1988-12-30 | Bristol-Myers Squibb Pharmaceutical Research Institute |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.